Summary & Overview
CPT 81551: Prostate Cancer Promoter Methylation Risk Score
CPT code 81551 covers a molecular diagnostic laboratory assay that assesses promoter methylation in three genes and uses an algorithm combining test results with patient data to produce a score estimating the likelihood of finding prostate cancer on repeat biopsy after an initial negative biopsy. This test matters nationally as precision diagnostics increasingly guide repeat biopsy decisions, potentially reducing unnecessary procedures and focusing surveillance on higher-risk patients. Key payers included in the analysis are Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare.
Readers will learn what CPT code 81551 represents clinically and operationally, the typical site of service and service type, and which major payers cover or evaluate the test. The publication summarizes common modifiers and highlights where input data are not available. It also provides context on clinical utility for patients with prior negative prostate biopsy and what stakeholders—laboratories, clinicians, and payers—typically consider when implementing or reviewing coverage for algorithm-based molecular tests. Policy, coding guidance, and reimbursement trends relevant to molecular risk-score assays are summarized for a national audience.
Billing Code Overview
CPT code 81551 describes a laboratory-based clinical test that measures promoter methylation of three specified genes and applies an algorithmic analysis combining the methylation results with patient data to generate a score predicting the likelihood of detecting prostate cancer on repeat biopsy for patients who previously had a negative prostate biopsy.
Service type: Molecular diagnostic laboratory test with algorithmic (proprietary) risk scoring.
Typical site of service: Clinical molecular laboratory with specimen collection usually performed at an outpatient clinic or physician office; testing and analysis occur in a certified laboratory.
Data not available in the input.
Clinical & Coding Specifications
Clinical Context
A 62-year-old man with a prior negative transrectal ultrasound-guided prostate biopsy and persistently elevated or rising prostate-specific antigen (PSA) is referred for molecular risk stratification to inform the need for repeat biopsy. The clinician orders a promoter methylation assay of the three genes specified by 81551. A blood or urine sample is collected at an outpatient clinic or sent from a urology practice to a certified molecular laboratory. The laboratory performs the technical methylation testing, integrates patient-specific data (for example age, PSA, and prior biopsy status) with the methylation results using the proprietary algorithm, and reports a quantitative risk score indicating the likelihood of detecting prostate cancer on repeat biopsy. The report is returned to the ordering urologist, who reviews the score alongside clinical factors to discuss surveillance versus repeat biopsy with the patient. Typical sites of service include outpatient urology clinics, ambulatory surgical centers for specimen collection, and independent reference molecular laboratories that perform the testing and reporting.
Coding Specifications
| Modifier | Description | When to Use |
|---|---|---|
26 | Professional component | Use when billing only the professional interpretation component if applicable and separated from the technical lab charge. |